for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BIOTON SA

BIOP.WA

Latest Trade

3.98PLN

Change

-0.02(-0.50%)

Volume

13,980

Today's Range

3.91

 - 

4.02

52 Week Range

3.88

 - 

5.86

As of on the Warsaw Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Bioton Q3 Net Loss Narrows To 7.3 Mln Zlotys

Dec 2 (Reuters) - Bioton SA <BIOP.WA>::REPORTED ON FRIDAY Q3 NET LOSS OF 7.3 MILLION ZLOTYS VERSUS LOSS OF 18.6 MILLION ZLOTYS YEAR AGO.Q3 REVENUE 44.9 MILLION ZLOTYS VERSUS 49.1 MILLION ZLOTYS YEAR AGO.

Jia Wei Wang Lowers His Stake In Bioton To 0.29% From 12.07%

Nov 4 (Reuters) - Bioton SA <BIOP.WA>::JIA WEI WANG LOWERS HIS STAKE IN CO TO 0.29% FROM 12.07%.

Bioton Announces Stake Changes

Oct 31 (Reuters) - Bioton SA <BIOP.WA>::SAYS DONGREN INVESTMENT LOWERS ITS STAKE IN CO TO 5% FROM ABOUT 24.79%.SAYS YIFAN PHARMACEUTICAL INDIRECTLY ACQUIRES 31.65% IN CO STAKE.SAYS YIFAN PHARMACEUTICAL INDIRECTLY HOLDS 19.79% CO STAKE BY DONG REN AND 11.86% CO STAKE BY PERFECT TREND.

Bioton Q2 Net Result Turns To Loss Of 87.5 Mln Zlotys

Oct 1 (Reuters) - Bioton SA <BIOP.WA>: :REPORTED ON MONDAY Q2 NET LOSS OF 87.5 MILLION ZLOTYS VERSUS PROFIT OF 66.3 MILLION ZLOTYS YEAR AGO.Q2 REVENUE OF 72.3 MILLION ZLOTYS VERSUS 85.0 MILLION ZLOTYS YEAR AGO.

Bioton Books Impairment Loss To Affect Its H1 Net Result

Sept 25 (Reuters) - Bioton SA <BIOP.WA>::RESOLVES TO BOOK IMPAIRMENT LOSS WHICH WILL AFFECT H1 CONSOLIDATED NET RESULT BY 100.7 MILLION ZLOTYS.SAID IMPAIRMENT LOSS REGARDS UPDATED VALUE OF COMPANY'S ASSETS IN ITS UNIT BIOLEK.

Bioton Says Biomm Terminates Deal For Commercialization Of Recombinant Human Insulin In Brazil

Sept 9 (Reuters) - Bioton SA <BIOP.WA>::SAID ON SATURDAY THAT IT HAS RECEIVED FROM BRAZIL-BASED BIOMM A DECLARATION OF THE TERMINATION OF DEAL FOR THE COMMERCIALIZATION OF RECOMBINANT HUMAN INSULIN IN THE TERRITORY OF BRAZIL .THE MAIN REASON FOR TERMINATION INDICATED BY BIOMM WAS THE FAILURE TO SIGN THE AGREEMENT BETWEEN BIOMM AND THE MINISTRY OF HEALTH OF BRAZIL REGARDING THE SUPPLY INSULIN TO BRAZIL .IN ADDITION, THE AGREEMENT BETWEEN BIOMM AND THE MINISTRY OF HEALTH OF BRAZIL WAS TEMPORARILY SUSPENDED IN AUGUST BY THE NATIONAL HEALTH SURVEILLANCE AGENCY - ANVISA.ALSO, PRODUCT REGISTRATION AT THE BRAZILIAN NATIONAL HEALTH SURVEILLANCE AGENCY HAS NOT BEEN GRANTED.BIOTON SAYS IT WILL ANALYZE THE LEGAL ISSUES OF TERMINATION IN ORDER TO CONDUCT THE FURTHER STEPS.BIOTON SAYS IT IS COMPLETING CLINICAL TRIALS AND REGARDLESS OF BIOMM'S DECISION, IT WILL CONTINUE TO REGISTER ON THE BRAZILIAN MARKET.

Yifan Pharmaceutical To Invest 716.3 Mln Yuan For 31.65% Stake In Bioton S.A.

Sept 2 (Reuters) - Yifan Pharmaceutical <002019.SZ>::SAYS IT PLANS TO BUY DONGREN SINGAPORE, PERFECT TREND VENTURES FOR A COMBINED 716.3 MILLION YUAN ($100.99 million) IN ORDER TO OWN STAKE IN BIOTON S.A. <<<BIOP.WA>>>.SAYS IT WILL BECOME BIOTON'S BIGGEST SHAREHOLDER WITH 31.65% HOLDINGS AFTER THE TRANSACTIONS.

Bioton Says Kelipond Investment Ltd Acquires 11.86% Stake In Perfect Trend Ventures

Aug 29 (Reuters) - Bioton SA <BIOP.WA>::SAYS KELIPOND INVESTMENT LIMITED ACQUIRES 11.86% STAKE IN PERFECT TREND VENTURES.

Bioton Says China-Based Harbin Gloria Pharmaceuticals Terminates Distribution Deal

Aug 19 (Reuters) - Bioton S.A. <BIOP.WA>::SAID ON FRIDAY THAT HARBIN GLORIA PHARMACEUTICALS HAS TERMINATED DEAL FOR SUPPLY AND DISTRIBUTION OF BIOTON'S INSULIN PRODUCTS ON CHINESE MARKET.SAID THAT HARBIN GLORIA PHARMACEUTICALS HAS CITED CHANGES ON CHINESE PHARMACEUTICAL MARKET AS REASON FOR TERMINATION OF DEAL .HARBIN GLORIA PHARMACEUTICALS ALSO SAID THAT IT WAS UNABLE TO MEET THE SALES FORECASTS AGREED IN DEAL.DEAL WILL BE AUTOMATICALLY TERMINATED AFTER 6 MONTHS .SAID THAT FOR A LONG TIME THERE HAVE BEEN PROBLEMS WITH IMPLEMENTATION OF DEAL BY HARBIN GLORIA PHARMACEUTICALS .SAID THIS SITUATION WAS REFLECTED IN FINANCIAL STATEMENTS OF COMPANY IN 2018 AND WILL AFFECT ITS RESULTS IN 2019.

Uniapek Lowers Its Stake In Bioton To 5% From 19.79%

July 22 (Reuters) - Bioton SA <BIOP.WA>::SAYS UNIAPEK LOWERS ITS STAKE IN CO TO 5% FROM 19.79%.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up